A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs RO 7020531 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 17 Aug 2017 Planned End Date changed from 22 Dec 2018 to 19 Apr 2019.
- 17 Aug 2017 Planned primary completion date changed from 22 Dec 2018 to 19 Apr 2019.
- 10 Jun 2017 Biomarkers information updated